Company history

Sanseido was founded in Kobe in October 1898. A Japanese drug wholesaler earns on the drug-price spread — the gap between the price it pays the manufacturer and the price it charges hospitals and pharmacies — and Kobe, whose customs house made it one of the three great ports for imported Western medicines alongside Yokohama and Osaka, was a good place to stand in the middle of that flow. The founder’s name has not survived into the company’s modern filings; the official chronology records only the single line that the business began in Kobe.

Incorporation came in May 1923, with capital of ¥200,000, turning a merchant house into a joint-stock wholesaler serving western Japan — in the very year the Great Kanto Earthquake wrecked the distribution network of eastern Japan and left the western wholesalers supplying it. Through the wartime allocation regime and the postwar recovery, Sanseido remained what almost every Japanese drug wholesaler then was: a regional firm tied to particular manufacturers by exclusive-agency custom, growing with national health insurance and the boom in prescription medicines.

The model worked for as long as the spread held. From 1992 the biennial official price revisions began cutting wholesalers’ margins by double-digit percentages, and a regional firm buying alone could no longer negotiate with manufacturers. Scale was the only remaining answer, and the whole industry began to consolidate toward four national wholesalers.

Sanseido listed on the second sections of the Tokyo and Osaka exchanges in September 1995 — the year the Great Hanshin earthquake struck its home city, so that the company was rebuilding supply to damaged Kansai hospitals and building a capital-market platform at the same time. Promotion to the first sections followed in 1997. What the listing really bought was not prestige but currency: cash, and tradable shares with which to take part in the consolidation everyone could see coming.

In April 2000 Sanseido merged with Kuraya and Tokyo Pharmaceutical to form Kuraya Sanseido and moved its head office from Kobe to Chuo-ku, Tokyo. Japan’s competition authority recorded the purpose plainly: to cope with a harsh operating environment and strengthen the management base. The combined firm was the largest drug wholesaler in the country — and, at ¥1,073.0 billion of sales in the year to March 2001, earned an operating profit of only ¥1.9 billion on it.

From 2003 the enlarged company began buying regional wholesalers outright — Ushioda Mikunido in March, Izutsu Yakuhin and Heisei Yakuhin in September — renaming them under the Kuraya Sanseido banner while leaving their local trading relationships intact. In December it delisted from Osaka and consolidated on Tokyo. Three years after the merger, a Kobe regional wholesaler had become a national network run from the centre of Tokyo.

The restructuring of 2004 finished the map and then changed the shape of the company. Evalus (western Honshu and Shikoku) and Atol (Kyushu and Okinawa) were acquired in April, completing national coverage; in October the group split itself into a holding company, Mediceo Holdings, with the wholesale business carried by a new Kuraya Sanseido. The holding structure existed to keep acquiring — it let the group absorb firms without dissolving the local brands and relationships it was paying for.

It was used at once. In October 2005 Mediceo took over Paltac, the largest wholesaler of toiletries, cosmetics and over-the-counter medicines, and renamed itself Mediceo Paltac Holdings. Animal medicines followed in 2007 (Maruzen Yakuhin), household goods and food distribution in 2008 (Kobasho). In October 2009 a further company split moved the drug business into Mediceo and left a pure holding company at the top, renamed Medipal Holdings — the first name under which the Kobe, Tokyo and Osaka lineages stood together.

By 2010 the group had three legs: prescription medicines, consumer goods, and animal health, the last consolidated into MP Agro. Paltac was floated separately on the Tokyo and Osaka exchanges that March, a parent-child listing meant to preserve its neutrality toward the drugstore chains it served. Watanabe Shuichi, who had joined Kuraya in 1979, became president in 2012. And the numbers had begun to say something awkward: in the year to March 2016 group sales reached ¥3,028.2 billion, but consumer goods, at less than a third of the revenue of the drug business, were earning an operating margin roughly twice as high. What the core business could no longer defend, the acquisition was earning.

The second half of the 2010s was steady rather than dramatic: sales up about 6% and operating profit up about a third between the years to March 2017 and March 2020, with the consumer-goods segment supplying most of the growth. Then COVID-19 cut across it — operating profit fell 27% in the year to March 2021 as patients stayed away from clinics, and the prescription-medicine segment’s profit dropped by 60% while masks and disinfectant sold and cosmetics did not. Recovery took three years; the year to March 2024 set a group record, and the following year lifted operating profit to ¥55.6 billion.

The medium-term plan running to March 2027 was given the deliberately blunt title “Change the 卸 Forever” — change the wholesaler, permanently — with a 9% return on equity as its target. Behind the slogan was an admission: the spread that had paid for everything since 1898 was not coming back, so the group would have to be paid for something else. It bought its way into adjacencies once more — chemicals and food ingredients (Sumitomo Pharma Food & Chemical in 2023; Higashinana in 2023, fourteen years after the first alliance), and health data (Premedica and Flora Discovery in 2024, extending the logic of the 2013 Medie deal from shipment records to health and microbiome data).

Two events closed the period. In May 2025 Watanabe’s treatment for malignant lymphoma was disclosed and the company moved to two representative directors, with vice-president Chofuku Yasuhiro — a 1977 entrant to Sanseido — sharing authority. And in May 2026 Medipal announced a tender offer for the 47.6% of PALTAC it did not own, at $42 (¥6,650) a share and $1.2B (¥192bn) in total, ending the parent-child listing. Twenty-one years after buying the company that had been earning its profit, it finally put it back inside.